Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6TLM

ROR(gamma)t ligand binding domain in complex with allosteric ligand compound 13 (Glenmark)

Summary for 6TLM
Entry DOI10.2210/pdb6tlm/pdb
DescriptorNuclear receptor ROR-gamma, 4-[1-[2,6-bis(chloranyl)phenyl]carbonyl-5-methyl-thieno[3,2-c]pyrazol-3-yl]benzoic acid (3 entities in total)
Functional Keywordsnuclear receptor, allosteric, inverse agonist, inhibitor, gene regulation
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight30945.46
Authors
de Vries, R.M.J.M.,Meijer, F.A.,Brunsveld, L. (deposition date: 2019-12-03, release date: 2020-03-04, Last modification date: 2024-01-24)
Primary citationde Vries, R.M.J.M.,Doveston, R.G.,Meijer, F.A.,Brunsveld, L.
Elucidation of an Allosteric Mode of Action for a Thienopyrazole ROR gamma t Inverse Agonist.
Chemmedchem, 15:561-565, 2020
Cited by
PubMed Abstract: The demand for allosteric targeting of nuclear receptors is high, but examples are limited, and structural information is scarce. The retinoic acid-related orphan receptor gamma t (RORγt) is an important transcriptional regulator for the differentiation of T helper 17 cells for which the first, and some of the most promising, examples of allosteric nuclear receptor modulation have been reported and structurally proven. In a 2015 patent, filed by the pharmaceutical company Glenmark, a new class of small molecules was reported that act as potent inverse agonists for RORγt. A compound library around the central thienopyrazole scaffold captured a clear structure-activity relationship, but the binding mechanism of this new class of RORγt modulators has not been elucidated. Using a combination of biochemical and X-ray crystallography studies, here the allosteric mechanism for the inverse agonism for the most potent compound, classified in the patent as "example 13", is reported, providing a strongly desired additional example of allosteric nuclear receptor targeting.
PubMed: 32053744
DOI: 10.1002/cmdc.202000044
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.321 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon